Keyword: durvalumab

Eli Lilly headquarters

8. Eli Lilly

Eli Lilly spent nearly a quarter of its income on R&D last year, putting it near the top of its peers in percentage terms, and saw some of that spend pay off—overall, however, last year was a mixed bag for the company’s research.
AstraZeneca

6. AstraZeneca

AstraZeneca had a pretty rough few years of R&D setbacks and failures up until 2012, when its former chief, David Brennan, was all but pushed out as a result. But things seem to have steadied somewhat since Pascal Soriot took the helm.

AstraZeneca pulls PD-L1 combo test, RSV candidate

It’s the fourth-quarter clear out, and AstraZeneca has pulled the plug on a combo of its immuno-oncology candidate as well as axing a test of its biologic arm’s RSV drug as it sheds some more light on its tests in head and neck cancers.